Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 20, 2024
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 20, 2023
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: June 09, 2022
Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors.
Journal: Investigational new drugs
Published: August 03, 2021
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.
Journal: Journal of hematology & oncology
Published: May 28, 2021
A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
Journal: Clinical breast cancer
Published: March 17, 2021
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 29, 2021
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Journal: British journal of cancer
Published: April 24, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 20, 2020
Last Updated: 09/26/2026